Zealand Pharma A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Emmanuel Dulac PharmD, MBA
- Full Time Employees
- 237
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Sydmarken 11 Copenhagen Denmark 2860
- IPO Date
- Aug 9, 2017
- CIK
- 0001674988
- Website
- zealandpharma.com
- Similar Companies
- Business
- Zealand Pharma A/S, a biotechnology company focused on the discovery, design, development, and commercialization of innovative peptide-based medicines addressing unmet medical needs, operates primarily in the areas of obesity, rare diseases, and chronic inflammation. Founded in 1998 and headquartered in Søborg, Denmark, with additional operations in the United States, the company offers a pipeline of investigational candidates including petrelintide, a long-acting amylin analog for weight management; dapiglutide, a long-acting GLP-1/GLP-2 receptor dual agonist targeting obesity and low-grade inflammation; survodutide, a long-acting glucagon/GLP-1 receptor dual agonist licensed to Boehringer Ingelheim for obesity and metabolic dysfunction-associated steatohepatitis; ZP6590, a GIP receptor agonist for obesity; dasiglucagon for continuous infusion in congenital hyperinsulinism and other formulations such as Zegalogue for severe hypoglycemia; glepaglutide, a long-acting GLP-2 analog for short bowel syndrome; ZP9830, a Kv1.3 ion channel blocker for T-cell-driven autoimmune diseases; and ZP10068, a complement C3 inhibitor for complement-mediated diseases. Zealand Pharma targets patients with metabolic, gastrointestinal, and inflammatory conditions globally through research, clinical development, and strategic partnerships. In recent developments, the company entered an exclusive collaboration and licensing agreement with Roche in March 2025 to co-develop and co-commercialize petrelintide as a monotherapy and in fixed-dose combination with Roche's CT-388 for obesity, providing upfront payments of USD 1.65 billion and potential total consideration up to USD 5.3 billion; closed this agreement in May 2025 with Phase 2b ZUPREME trials advancing; submitted a Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome; reported positive topline results from a 28-week Phase 1b trial of dapiglutide; completed an upsized equity offering raising approximately DKK 835 million in June 2024 to fund obesity programs; and appointed Steven Johnson as Chief Development Officer to strengthen leadership in obesity innovation.
Company News
Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
Zealand Pharma Announces Financial Results for the First Half of 2026
Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide
Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)
Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Zealand Pharma: Transactions related to share buy-back program (week 29, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)